APA (7th ed.) Citation

K, P., JM, V., SD, N., JR, B., KJ, M., JA, W., . . . PL, Z. (2026). Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: Phase 1/2 BRUIN study. Blood advances, 10(7), 2441. https://doi.org/10.1182/bloodadvances.2025017489

Chicago Style (17th ed.) Citation

K, Patel, et al. "Pirtobrutinib, a Highly Selective, Noncovalent (reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study." Blood Advances 10, no. 7 (2026): 2441. https://doi.org/10.1182/bloodadvances.2025017489.

MLA (9th ed.) Citation

K, Patel, et al. "Pirtobrutinib, a Highly Selective, Noncovalent (reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study." Blood Advances, vol. 10, no. 7, 2026, p. 2441, https://doi.org/10.1182/bloodadvances.2025017489.